UK–(ENEWSPF)–10 April 2014. Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. This is according to the updated Cochrane evidence review, published today by The Cochrane Collaboration, the independent, global healthcare research network, and the BMJ. Evidence from treatmenttrials confirms increased risk of suffering from nausea and vomiting. And when Tamiflu…
